Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Perri

Showing results (51-60 of 58) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 58 results.
ESMO Open|September 4, 2025
Gene actionability according to the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) in No Specific Molecular Profile (NSMP) endometrial cancerL Mastrantoni, F Camarda, C Parrillo, et al.
Science (New York, N.Y.)|November 16, 2023
Nickel-catalyzed ester carbonylation promoted by imidazole-derived carbenes and saltsChangho Yoo, Shrabanti Bhattacharya, Xin Yi See, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 27, 2022
The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancerK E Francis, S I Kim, M Friedlander, et al.
ESMO Open|May 30, 2025
Response to letter re: Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world studyC Marchetti, A Fagotti, R Fruscio, et al.
ESMO Open|April 2, 2025
Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world studyC Marchetti, A Fagotti, R Fruscio, et al.
ESMO Open|May 30, 2025
Response to letter re: Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study: Not all BRCA mutations are equal: functional context and mutation type as co-determinants of PARP inhibitor responseC Marchetti, A Fagotti, R Fruscio, et al.
ESMO Open|November 19, 2025
PARPi and myeloid neoplasms; the Italian MITO-MaNGO experience based on a multicentric surveyM Turinetto, C Marchetti, G Scandurra, et al.
Canadian Journal of Surgery. Journal Canadien De Chirurgie|April 30, 2022
Abstracts of presentations to the Annual Meetings of the Canadian Association of General Surgeons Canadian Association of Thoracic Surgeons Canadian Hepato-Pancreato-Biliary Society Canadian Society of Surgical Oncology Canadian Society of Colon and Rectal Surgeons: Victoria, BC Sept. 10-13, 2009R Nenshi, E Kennedy, N N Baxter, et al.
Pageof 6

Showing results (51-60 of 58) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 58 results.
ESMO Open|September 4, 2025
Gene actionability according to the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) in No Specific Molecular Profile (NSMP) endometrial cancerL Mastrantoni, F Camarda, C Parrillo, et al.
Science (New York, N.Y.)|November 16, 2023
Nickel-catalyzed ester carbonylation promoted by imidazole-derived carbenes and saltsChangho Yoo, Shrabanti Bhattacharya, Xin Yi See, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 27, 2022
The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancerK E Francis, S I Kim, M Friedlander, et al.
ESMO Open|May 30, 2025
Response to letter re: Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world studyC Marchetti, A Fagotti, R Fruscio, et al.
ESMO Open|April 2, 2025
Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world studyC Marchetti, A Fagotti, R Fruscio, et al.
ESMO Open|May 30, 2025
Response to letter re: Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study: Not all BRCA mutations are equal: functional context and mutation type as co-determinants of PARP inhibitor responseC Marchetti, A Fagotti, R Fruscio, et al.
ESMO Open|November 19, 2025
PARPi and myeloid neoplasms; the Italian MITO-MaNGO experience based on a multicentric surveyM Turinetto, C Marchetti, G Scandurra, et al.
Canadian Journal of Surgery. Journal Canadien De Chirurgie|April 30, 2022
Abstracts of presentations to the Annual Meetings of the Canadian Association of General Surgeons Canadian Association of Thoracic Surgeons Canadian Hepato-Pancreato-Biliary Society Canadian Society of Surgical Oncology Canadian Society of Colon and Rectal Surgeons: Victoria, BC Sept. 10-13, 2009R Nenshi, E Kennedy, N N Baxter, et al.
Pageof 6